Freenome
PublicFreenome is now publicly traded
The data on this page reflects Freenome's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
PIPE
Dec 5, 2025
Est. Valuation at Exit
$965M
Total Funding Raised
$1.6B
Company Overview
Freenome operates in Biotech and is based in South San Francisco, California. It has raised $1.6B.
Freenome is a biotechnology company that develops noninvasive blood-based screening tests for early cancer detection using a multiomics platform powered by machine learning.
Sector
Biotech
Verticals
HealthTech, Life Sciences, Oncology
AI Layer
Application
Freenome Comparables
Compare Freenome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Universal Diagnostics | 87% | |
| Guardant Health | 83% | |
| Delfi Diagnostics | 81% |
For institutional investors. Book with your work email.
Freenome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Dec 5, 2025 | ||||
| VC Round | Feb 15, 2024 | ||||
| Series D Extension | Jan 11, 2022 | ||||
| Series D | Dec 7, 2021 | ||||
| Series C | Aug 26, 2020 | ||||
Series B | Jul 24, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Freenome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series C |
| Andreessen Horowitz | Series B, Series C, Series A, Seed, VC Round, Series D |
| S32 | VC Round, Series B, Series D, Series C, Series A |
| Soleus Capital | Series D, Series C |
| Bain Capital Life Sciences | VC Round, Series D, Series D Extension, PIPE, Series C |
| Janus Henderson Group | Series D, Series C |
| RA Capital Advisors | Series D, VC Round |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueNov 10, 2026
Freenome reports $184M in Q3 '26 revenue, specifically $183.5 million, including $180.0 million from its collaboration and license agreement after FDA approval of SimpleScreen CRC, in California.
- has_lossNov 10, 2026
Freenome reported a net loss of $64.5M a year earlier, compared with net income of $60.1 million in the current period.
- has_revenueNov 10, 2026
Freenome guides to $2 million-$4 million of Q4 '26 revenue, with a $3M midpoint, and expects no meaningful testing revenue or royalties.
- is_developingOct 14, 2026
Freenome is developing noninvasive screening tests for colorectal cancer and other common cancers to support earlier detection through routine blood draws.
- is_developingOct 11, 2026
Freenome is developing SimpleScreen(TM) CRC for colorectal cancer screening to increase cancer detection among millions of at-risk individuals.
For institutional investors. Book with your work email.
Freenome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.